Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.30 | 33.93 | 49.61 | 37.00 |
| Expenses | 15.06 | 11.63 | 12.17 | 14.40 | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating Profit | -1.98 | -2.48 | -1.62 | -1.78 | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 | 0.55 |
| OPM % | -15.14% | -27.10% | -15.36% | -14.10% | -15.49% | -13.13% | -3.40% | -45.14% | -31.96% | -12.02% | 0.24% | 1.49% |
| Other Income | -0.03 | -0.02 | 0.26 | 0.02 | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0.00 | 0.17 | 0.02 |
| Interest | 0.34 | 0.36 | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.83 | 0.69 | 0.64 | 0.65 | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 |
| Profit before tax | -3.18 | -3.55 | -2.59 | -2.82 | -2.77 | -4.97 | -3.80 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax % | -0.63% | 6.48% | -409.27% | -51.42% | 2.89% | -20.72% | -43.42% | -25.03% | -23.45% | -23.38% | 32.81% | -15.94% |
| Net Profit | -3.16 | -3.78 | 8.02 | -1.36 | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.70 | -2.10 |
| EPS in Rs | -0.94 | -1.13 | 2.40 | -0.38 | -0.80 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 | -0.57 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Expenses | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 | 143 |
| Operating Profit | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | -34% | -59% | -31% | -10% | -57% | 7% | 2.4% | -23% | -24% | -9% | -14% | -6% |
| Other Income | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 | 7 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 | 2 |
| Profit before tax | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -14 | -22 | -17 |
| Tax % | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -28% | -21% | |
| Net Profit | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS in Rs | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 25% | 17% | 54% | 21% | ||
| Compounded Profit Growth | % | % | -28% | 8% | ||
| Stock Price CAGR | 16% | 7% | 13% | -30% | ||
| Return on Equity | % | % | % | % |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -63 | -80 |
| Borrowings | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other Liabilities | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total Liabilities | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed Assets | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 |
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Cash from Investing Activity | 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Cash from Financing Activity | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free Cash Flow | -7 | -1 | -0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -8 | -41 |
| CFO/OP | 104% | -20% | -13% | -33% | 396% | 35% | -37% | -106% | 23% | 135% | -29% | 182% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working Capital Days | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
| ROCE % | -1% | -47% | -42% | -33% | -34% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 29.73% | 29.73% | 29.73% | 33.68% | 53.28% | 51.12% | 51.12% | 57.95% | 57.95% | 55.93% | 56.53% | 56.53% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Public | 70.24% | 70.24% | 70.24% | 66.28% | 46.69% | 48.84% | 48.84% | 42.02% | 42.01% | 44.05% | 43.44% | 43.43% |
| No. of Shareholders | 8,972 | 9,051 | 10,102 | 9,970 | 10,154 | 10,107 | 10,030 | 10,094 | 10,179 | 10,215 | 10,205 | 10,196 |
Fundamentals
Market Cap₹ 177 Cr.
Current Price₹ 47.9
Book Value₹ -11.5
ROCE-33.6 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)21%
Compounded Profit Growth (TTM)8%
Standalone figures.
Valuation
Market capRs 178 Cr
Enterprise valueRs 285 Cr
Price to book-4.16x
Price to sales1.32x
EV / sales2.11x
Earnings yield-7.64%
P/B, 3-year average-6.83x
P/B, 5-year average-4.52x
Profitability
Operating margin (excl. other income)-13.57%
Operating margin (incl. other income)-13.32%
EBITDA margin-5.82%
Pre-tax margin-12.28%
Net profit margin-10.06%
Net margin, latest quarter-5.68%
ROE51.43%
ROCE-33.56%
ROA-17.35%
ROE, 3-year average35.64%
ROCE, 3-year average-36.05%
ROA, 3-year average-12.46%
ROE, 5-year average27.45%
ROCE, 5-year average-31.06%
ROA, 5-year average-13.27%
ROIC (approx.)-12.18%
Tax rate20.78%
Other income / net worth-0.68%
Growth
Sales growth (latest year)3.33%
Sales CAGR, 3 years53.89%
Sales CAGR, 5 years16.77%
Sales growth QoQ-25.42%
Sales growth YoY (latest quarter)144.55%
Per share
EPS (TTM)Rs -3.67
EPS (latest year)Rs -4.75
EPS (latest quarter)Rs -0.57
EPS, 3-year averageRs -2.86
EPS, 5-year averageRs -3.43
Book value per shareRs -11.54
Sales per shareRs 36.46
Cash flow per shareRs -7.50
Free cash flow per shareRs -11.09
Efficiency
Asset turnover0.94x
Fixed asset turnover2.37x
Inventory turnover4.00x
Inventory days91 days
Debtor days32 days
Debtors turnover11.26x
Creditor days174 days
Cash conversion cycle-37 days
Working capital days-119 days
Leverage
Total debtRs 110 Cr
Cash and bankRs 2 Cr
Net debtRs 107 Cr
Debt to equity-2.57x
Interest coverage-1.51x
Owners' fund to total sources-35.67%
Debt to assets91.54%
Cash flow
Cash from Operating Activity (latest year)Rs -28 Cr
Cash from Investing Activity (latest year)Rs -14 Cr
Cash from Financing Activity (latest year)Rs 43 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -41 Cr
FCFE (approx.: FCF + change in debt)Rs 6 Cr
Statement figures
Net sales (TTM)Rs 135 Cr
Net sales (latest year)Rs 113 Cr
Sales (latest quarter)Rs 37 Cr
Operating profit excl. other income (latest year)Rs -15 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -8 Cr
PBDT (TTM)Rs -14 Cr
Profit before tax (TTM)Rs -17 Cr
Tax (latest year)Rs -5 Cr
Net profit (TTM)Rs -14 Cr
Net profit (latest year)Rs -18 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 118 Cr
Total expenditure (latest year)Rs 128 Cr
Total income (latest year)Rs 113 Cr
Share capitalRs 37 Cr
ReservesRs -80 Cr
Shareholders' fundsRs -43 Cr
Total assetsRs 120 Cr
Net blockRs 48 Cr
InvestmentsRs 0 Cr
ReceivablesRs 10 Cr
InventoryRs 29 Cr
Other liabilitiesRs 53 Cr
Shares outstanding (crore)3.70
Ownership
Promoter holding56.53% (-1.42 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 524636 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.5% | -2.8% | -2.8 pts |
| 1 month | -19.3% | -6.8% | -12.5 pts |
| 3 months | -1.0% | -7.6% | +6.6 pts |
| 3 years | +44.7% | +14.2% | +30.5 pts |
| 5 years | +42.4% | +27.9% | +14.5 pts |
Red flags
F-score 1 of 8| serious | Negative equity Shareholders' equity is negative |
| explain | Share dilution Share count up 0% in a year, 161% in three |
| explain | Debt up, profit down Borrowings up 76% while net profit fell in 2026 |
| look | Inventory outrunning sales Inventory grew 43% vs sales +3% in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹37 Cr +144.5% vs Jun 2025.
Net loss ₹2 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd (524636) has a market capitalisation of Rs 177 Cr. at the 2026-10-01 close.
What were Oxygenta Pharmaceutical Ltd's latest quarterly results?
In the Jun 2026 quarter, Oxygenta Pharmaceutical Ltd sales was Rs 37 Cr (+144.5% vs Jun 2025) with a net loss of Rs 2 Cr.